Dimensional Fund Advisors LP Reduces Stock Position in Hims & Hers Health, Inc. $HIMS

Dimensional Fund Advisors LP cut its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 39.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 660,241 shares of the company’s stock after selling 424,976 shares during the period. Dimensional Fund Advisors LP’s holdings in Hims & Hers Health were worth $13,707,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of HIMS. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health during the third quarter worth about $28,000. Silicon Valley Capital Partners acquired a new position in Hims & Hers Health in the 3rd quarter worth approximately $48,000. Flagship Harbor Advisors LLC acquired a new position in Hims & Hers Health in the 4th quarter worth approximately $28,000. Bogart Wealth LLC raised its position in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after buying an additional 632 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in Hims & Hers Health by 273.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 23,726 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the sale, the insider owned 181,861 shares in the company, valued at approximately $6,365,135. This trade represents a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the transaction, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at $13,611,906. The trade was a 3.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 83,126 shares of company stock worth $2,711,339. Insiders own 11.76% of the company’s stock.

Hims & Hers Health Stock Up 6.5%

Shares of HIMS stock opened at $31.58 on Friday. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $65.30. The stock has a market cap of $7.31 billion, a P/E ratio of -350.89, a P/E/G ratio of 88.90 and a beta of 2.40. The stock has a 50 day moving average of $31.86 and a 200 day moving average of $26.10. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.20 EPS. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.03 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on HIMS shares. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a report on Friday, May 22nd. Citigroup raised their target price on shares of Hims & Hers Health from $28.00 to $35.00 and gave the stock a “neutral” rating in a report on Thursday, July 23rd. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Weiss Ratings lowered shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a report on Tuesday, May 12th. Finally, Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $31.43.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.